logo
Plus   Neg
Share
Email

Stock To Watch: ObsEva's PRIMROSE 2 Trial Meets Goals

ObsEva SA's (OBSV) phase III study of Linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids, dubbed PRIMROSE 2, has yielded positive results.

The PRIMROSE 2 trial, conducted in Europe and the US, evaluated the efficacy and safety of once-daily oral Linzagolix, including 100 mg and 200 mg doses, both with and without hormonal add-back therapy (ABT).

In the trial, which enrolled 535 women with heavy menstrual bleeding (HMB) due to uterine fibroids, the responder rate was 93.9% for women receiving 200 mg oral Linzagolix with ABT and 56.7% for women receiving 100 mg oral Linzagolix without ABT compared to 29.4% in the placebo group.

Responders were defined as patients with menstrual blood loss volume of = 80 mL and = 50% reduction from baseline in menstrual blood loss volume at 24 weeks.

Both doses achieved important clinically relevant secondary endpoints including amenorrhea, reduction in pain, improvement in quality of life and improvement in hemoglobin levels, noted the Company.

Results from the second pivotal study of Linzagolix, dubbed PRIMROSE 1, conducted in the US, are expected in the second quarter of 2020.

If everything goes well, the company expects to seek approval for Linzagolix in Europe by year-end 2020 and in the U.S. by the first quarter of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT